Company research

Anteris Technologies Global Corp. Common Stock (AVR) stock fundamentals

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel

As of 2026-10-08

Exchange
XNAS
Sector
Healthcare
Industry
Medical Instruments & Supplies

Company overview

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.

Daily valuation snapshot

These values are from the stored daily market snapshot dated 2026-10-08. They are not a live quote.

Daily close (USD)$6.63
Market capitalization (USD)$646,149,682.62
Price / earnings (TTM)Not reported
Price / book2.57

Continue the research

Read public ownership disclosures separately from company fundamentals. Test a strategy against dated historical observations before evaluating its assumptions; a past result is not a live trading outcome.